RT Journal Article
SR Electronic
T1 Seroprevalence of COVID-19 in Palestine in 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.04.21263131
DO 10.1101/2021.10.04.21263131
A1 Rayan, I
A1 Qaddomi, SE
A1 Najjar, O
A1 Abbas, S
A1 Mousa, K
A1 Iraqi, L
A1 Abdelkreem Aly, E
A1 Abu Khader, K
A1 Barakat, A
A1 Salman, R
YR 2021
UL http://medrxiv.org/content/early/2021/10/07/2021.10.04.21263131.abstract
AB COVID-19 affected different countries in different ways. Palestine had recorded over 140,000 cases by the end of 2020. The WHO/PNIPH, WHO/EMRO, and the Palestinian MoH carried out a serological survey in Palestine in order to estimate the actual number of COVID-19 infections up to the end of December 2020. A sample stratified by region, district, residence area (urban, rural, and refugee camp), and accounting for gender, was taken from Gaza and the West Bank. Data from participants were also collected, including demographic, socio-economic, and health conditions. The results show that 39% of the Palestinian population (38% of the West Bank and 40% of Gaza) had been infected with COVID-19 by the end of December, almost 10 times the number detected by targeted Rt-PCR testing. Several factors were calculated to be significant such as diabetes, smoking, gender, age, and residence.Summary of findings The following table is a summary of all findings presented in this report. The P values in green are below 0.05, which makes the result statistically significant; red is not statistically significant. In binary comparisons (when comparing two numbers), the odds were calculated, meaning how much more likely the presence of seropositivity is if the condition is satisfied. For example, those who were previously diagnosed as COVID-19 positive using Rt PCR were 2.5 times as likely to be seropositive than those who were not diagnosed.View this table:Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research project was funded by the WHOAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the WHO/EMRO ethics board, and is in line with WHO ethics of conduct.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript